Wu Tai-Zhi, Liu Xiao-Hua, Zhang Fu-Li, Xie Mei-Hua
Shanghai Institute of Pharmaceutical Industry, Shanghai 200437, China.
Yao Xue Xue Bao. 2006 Jun;41(6):537-43.
To develop a new synthetic route for olmesartan medoxomil.
Olmesartan medoxomil was prepared from ethyl 4-(1-hydroxy-1-methylethyl)-2-propylimidazole-5-carboxylate via hydrolysis and lactonization to afford 4,4- dimethyl-2-propyl-4,6-dihydrofuro [3,4-d]-1H-imidazole-6-one which was condensed with 2-(triphenylmethyl)-5-[4'-(bromomethylbiphenyl)-2-yl] tetrazole, followed by esterification with 4-chloromethyl-5-methyl-1,3-dioxol-2-one, and deprotection. The chemical structure of the major impurity in condensation reaction is the regio-isomer in the imidazole moiety, and confirmed by single crystal X-ray diffraction. The corresponding regio-isomer of olmesartan medoxomil was synthesized from the impurity by similar method. Optimization of the condensation conditions reduced the impurity to a negligible quantity.
Synthesis of olmesartan medoxomil by the new route gave a product of 60% yield and above 99.0% purity. The content of olmesartan medoxomil regio-isomer was effectively controlled to less than 0.1%.
A novel synthetic route for olmesartan medoxomil was developed successfully. The olmesartan medoxomil regio-isomer is reported for the first time.
开发奥美沙坦酯的一条新合成路线。
以4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸乙酯为原料,经水解和内酯化反应制得4,4-二甲基-2-丙基-4,6-二氢呋喃并[3,4-d]-1H-咪唑-6-酮,该产物与2-(三苯甲基)-5-[4'-(溴甲基联苯)-2-基]四唑缩合,再用4-氯甲基-5-甲基-1,3-二氧杂环戊-2-酮进行酯化反应,最后脱保护。缩合反应中主要杂质的化学结构为咪唑部分的区域异构体,通过单晶X射线衍射得以确证。奥美沙坦酯相应的区域异构体由该杂质通过类似方法合成。缩合条件的优化使杂质含量降低到可忽略不计的程度。
采用新路线合成奥美沙坦酯,产物收率为60%,纯度高于99.0%。奥美沙坦酯区域异构体的含量有效控制在0.1%以下。
成功开发了一条新颖的奥美沙坦酯合成路线。首次报道了奥美沙坦酯区域异构体。